Global Venous Diseases Treatment Market - 2022-2029

Market Overview

Venous Diseases Treatment Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

The venous disease includes blood clots in the legs, arms, brains, lungs, or internal organs (kidney, spleen, liver), deep vein thrombosis, chronic venous insufficiency, varicose and spider veins, and ulcers in the vein. The treatment for this disease includes drug therapy, endovenous laser ablation or radiofrequency ablation (RFA), sclerotherapy, and surgery.

Market Dynamics

The Venous Diseases Treatment market growth is driven by the rise in the prevalence venoous disease, rising demand for laser ablation procedures, rising adoption of venous diseases treatment, increase in the geriatric population, and research activities.

The increasing prevalence of venous diseases is expected to drive the market growth

The rising prevalence of different venous diseases such as blood clots deep vein thrombosis, and chronic venous insufficiency is expected to boost the market over the forecast period. In 2021, a study reported by Bawakid et al. in Makah, Jeddah and Dammam mentioned an overall prevalence of chronic venous insufficiency of 45.6% in both males and females. Also, a prevalence study conducted in 2021, in primary health care centers in Qassim region of Saudi Arabia region revealed that the prevalence of varicose veins among male and female was 61.1%. A new questionnaire-based study coupled with Doppler ultrasonography was showed in Republic of Korea reported less prevalence of varicose veins in female nurses 16.18%. This could be allocated to the rapid of changes in lifestyle and advancement in access to health care. Those people with varicose veins, the most commonly CEAP class was C1 which indicates a mild form of the disease presenting as telangiectasia or reticular veins among females in this study. In addition, age is a major contributing risk factor that rises the development and progression of varicose veins in our body.

Increasing in age is a significant factor in further skin trophic changes, growth in the endovascular pressure, and inability of the superficial venous system. Moreover, a large study done in different locations of France in Europe reported that 72.7% of pregnant women are suffering from varicose veins. Also, higher Body Mass Index (BMI) is associated to more advanced stages of varicose veins. Furthermore, fast changes in lifestyle and increased awareness about varicose veins and its risk factors through easier access to health care specifically through social media drives the venous disease treatment market.

The high cost of Venous Diseases Treatment will hamper the growth of the market

However, side effects associated with veous disease treatment such as infection during venous ablation, soreness and inflammation, bruising, blood clots and, swelling. In addition, pain and heaviness in the legs and feet, especially after long a time standing or walking for long periods of time and ,burning, and cramping in the legs restarestraintsmarket growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global venous diseases treatment market. As per the article published in Sage journals in July 2020, The COVID-19 pandemic has resulted in deviation of healthcare resources such as critical supplies, workforce, emergency and intensive care unit (ICU) facilities of patients infected with coronavirus. Interuuptions in surgical procedures in most countries such as United States had been postponed or cancelled and operating room resources were focused on management of the pandemic. Restrictions to direct personal contact and social distancing have controlled the access to care. Patients with venous and lymphatic disorders or vascular anomalies faced difficulty to get expert care in pandemic. In addition, there is increasing evidence that COVID-19 with both arterial and venous thromboembolic (VTE) disease and extensive coagulopathies is additionally difficult of the diagnosis of the affected patients. As the situation is recovering from COVID-19 more patients with venous treatment can easily access the proper treatment which drives the market.

Segment Analysis

The chronic venous insufficiency segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic venous insufficiency segment is expected to boost the market over the period of the forecast. In 2022, the article published in Dermatol Therpeutics, chronic venous disorder (CVD) is most prevalent vascular disorder affecting up to 45% of the general population, with clinical relevation ranging from teleangiectasias to venous leg ulcers. The prevalence of CVD rises with age and it is more familiar in female than male. However, estimates of CVD prevalence vary widely from study to study 15-80% due to differences in study design and target population, and most of time CVD is underdiagnosed and undertreated, especially at lower severity levels. The pharmacological treatment can give proper symptomatic relief and it is considered as part of conservative treatment. Transcutaneous Lacer treatment is a safe and effective alternative option to sclerotherapy for treatment of C1 stage. Ultrasound-guided foam sclerotherapy (UGFS), high ligation and stripping, endovenous thermal ablation (EVTA) systems and non thermal non tumescent ablation systems are safe and effective first-line options for treatment of saphenous insufficiency.

Furthermore, in january 2022, The European Society for Vascular Surgery (ESVS) has published 2022 clinical practice guidelines on the management of chronic venous disease (CVD) of the lower limb to update its 2015 guidelines. The new guidelines foused on CVD of the lower limbs, related to pathology of the superficial, perforating and deep veins of the lower limb as well as to abdominal and pelvic venous pathology.

Geographical Analysis

North America region holds the largest market share of the global venous diseases treatment market

North America dominates the market for venous diseases treatment and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to technological advancement, presence of key players and easily availability of treatment. The article published in 2020 in J Vasc Surg Venous Lymphat Discord. Chronic venous insufficiency (CVI) resulting from venous reflux or obstruction leads to venous hypertension with edema, varicose veins, consequent pain, hyperpigmentation, and ulceration of the lower extremities. The CVI affects approximately 25 million adults in the United States region, with around 6 million suffering from advanced disease, and the annual cost of venous ulcer treatment and care is anticipated to be nearly $3 billion. Furthermore, for those people who are working for them CVI accounts for a loss of 2 million workdays per year, and almost 12% seek early retirement. Prolonged standing, Female sex, pregnancy, obesity; advanced lifestyle, venous reflux or obstruction, and deep venous thrombosis (DVT) are suspected risk factors for CVI. The increasing number of venous disease patient boosts the venous disease treatment market.

Competitive Landscape

The venous diseases treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Biolitec AG Untere Viaduktgasse, Teleflex Incorporated, B. Braun Melsungen Ag, Alma Lasers, Becton Dickinson and Company, and Koninklijke Philips N.V. among others. The major players are adopting several growth strategies such as treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the venous diseases treatment market globally.

For instance,

• In February 2022, Becton, Dickison, and Company acquired Venclose Inc., a contributor of solutions for the treatment of chronic venous insufficiency (CVI) a disease that is the result of malfunctioning valves and can lead to varicose veins.

Becton, Dickison and Company

Overview:

The Becton, Dickinson and Company is an American multinational company that manufactures and distributes instrument systems, medical devices, and reagents for treatment of various diseases including venous disease.

Treatment Type Portfolio:

Venclose radiofrequency (RF) Ablation System: This system offers transformative solutions to improve outcomes in patients for chronic disease and able to the transition into novel care settings.

The global venous diseases treatment market report would provide access to approximately 50+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.